New HPV cancer drug trial seeks safe dose
NCT ID NCT05976828
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This early-stage trial tests a drug called IBRX-042 in 12 adults with HPV-related cancers that have come back or worsened. The main goal is to find the safest dose and see what side effects occur. Participants get three injections, one every three weeks, and are closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV-RELATED CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Chan Soon-Shiong Institute for Medicine (CSSIFM)
El Segundo, California, 90245, United States
-
Texas Oncology Austin Central
Austin, Texas, 78731, United States
-
The University of Texas - MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.